Sign In
Buy DBVT
$15.82
+0.0900 (+0.572%)
At Close: Jul 02, 2026
DBV Technologies S.A. (DBVT) Discusses Regulatory Update and FDA Interactions for Viaskin Peanut Patch in Young Children Transcript
09:42am, Tuesday, 30'th Jun 2026
DBV Technologies S.A. (DBVT) Discusses Regulatory Update and FDA Interactions for Viaskin Peanut Patch in Young Children Transcript
Châtillon, France, June 29, 2026 DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review
DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index
04:30pm, Tuesday, 23'rd Jun 2026
Châtillon, France, June 23, 2026 DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock?
09:01am, Monday, 15'th Jun 2026
DBV Technologies (DBVT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price inc
DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference
07:00am, Tuesday, 09'th Jun 2026
Châtillon, France, June 9, 2026 DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq
Châtillon, France, June 8, 2026 DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 In the Phase 3 VITESSE study, V
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
04:30pm, Friday, 05'th Jun 2026
Châtillon, France, June 5, 2026 DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock M
DBV Technologies Announces the Results of its 2026 Combined General Meeting
04:30pm, Wednesday, 03'rd Jun 2026
Châtillon, France, June 3, 2026 DBV Technologies Announces the Results of its 2026 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR
Châtillon, France, June 2, 2026 DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN ® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy Th
Combined General Meeting of June 3, 2026
04:30pm, Wednesday, 13'th May 2026
Châtillon, France, May 13, 2026 Combined General Meeting of June 3, 2026 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DB
DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq
04:30pm, Tuesday, 12'th May 2026
Châtillon, France, May 12, 2026 DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – N
DBV Technologies Reports First Quarter 2026 Financial Results
04:30pm, Thursday, 30'th Apr 2026
Châtillon, France, April 30, 2026 DBV Technologies Reports First Quarter 2026 Financial Results Reported cash and cash equivalents of $229 million as of March 31, 2026 —providing funding into the s
Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year?
10:41am, Friday, 24'th Apr 2026
Here is how COMPASS Pathways PLC Sponsored ADR (CMPS) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year.
DBV Technologies: A Cohort-Driven Model That Could Support Blockbuster VIASKIN Revenue
05:55pm, Friday, 17'th Apr 2026
DBV Technologies S.A. (DBVT) reported positive Phase 3 VITESSE results for Viaskin Peanut, advancing toward blockbuster sales projections exceeding $2 billion. My model estimates Viaskin Peanut's U.S.
DBV Technologies (DBVT) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Tuesday, 14'th Apr 2026
DBV Technologies (DBVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
